BOEHRINGER-INGELHEIM
21.4.2022 10:02:12 CEST | Business Wire | Press release
It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why a tendon or ligament injury can be devastating for horse owners, riders and trainers. For equine athletes, the diagnosis may mean many months of treatment and rehabilitation with an unknown outcome, and potential for long term impact on their ability to perform.
Boehringer Ingelheim has now received approval in Europe for RenuTend™, the first product licensed to improve healing of tendon and suspensory ligament injuries in horses. RenuTend™ is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell® FORTE, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
“We are delighted to add RenuTend™ to our portfolio of stem cell products for horses, offering veterinarians a new therapeutic option for treating tendon and suspensory ligament injuries. This product demonstrates the company's commitment to bringing innovation to improve the lives of horses and the people who love them,” comments Liz Barrett, Head of Global Strategic Marketing, Equine at Boehringer Ingelheim. “RenuTend™ will allow more riders, owners and trainers to reimagine the dreams a tendon injury jeopardizes, by optimizing the possibilities for their horse to return to work with reduced potential for reinjury.”
Tendon and ligament lesions don’t always heal properly, as scar tissue can be less elastic than healthy tissue, and reinjury rates can be up to 80 percent. This can mean the end of a career for many horses. RenuTend™ is a targeted stem cell treatment with proven efficacy and repeatable results. It improves the quality of tendon healing by promoting parallel alignment of the right type of fibres and decreases the amount of scar tissue formed.
RenuTend™ will be available across the European Union. The approval for Great Britain is still pending.
Please click on the link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/animal-health/companion-animals/horses/stem-cell-therapy-tendon-and-ligament-injuries-horses
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005467/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Named a Leader in the 2026 Gartner® Magic Quadrant™ for Communications Platform as a Service18.5.2026 16:25:00 CEST | Press release
Recognized for Completeness of Vision and Ability to Execute Infobip is excited to share that global AI-first cloud communications platform Infobip has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Communications Platform as a Service. Check back for a complimentary copy of the full report soon! In Infobip’s view, this recognition reflects what the company has spent 20 years building: a communications platform that stays focused on what customers actually need and evolves as markets change. Infobip believes that recognition in a fast-moving market comes not from chasing trends, but from disciplined execution and a clear long-term vision. As Infobip marks its 20th year of operations, the company thinks the shift to agentic AI represents the most significant transformation in customer communications in our history. Infobip believes enterprises need a partner that empowers them to move from campaigns and rigid workflows to autonomous, goal-driven interactions, while r
Seoul Design Foundation Announces ‘Seoul Design AI Film Festival’ Call for Entries18.5.2026 16:00:00 CEST | Press release
Transforming DDP’s 222m Facade into a Global Canvas for AI Creators The Seoul Design Foundation (CEO Cha Kang Heui) is inviting visionaries worldwide to the Seoul Design AI Film Festival (SDAFF). This global competition aims to redefine the Dongdaemun Design Plaza (DDP)—the world’s largest atypical architecture—as a premier destination for AI-driven media art. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518044745/en/ An official poster for Seoul Design AI Film Festival (Image: Seoul Design Foundation) The DDP’s 222-meter curved exterior wall, a Guinness World Record holder for the "World's Largest 3D Mapping on an Atypical Building," will serve as the digital canvas for the winners. ‘Seoul Light DDP’ has already achieved global acclaim by winning the world’s top three design awards: iF, Red Dot, and IDEA. Bridging AI Technology and K-Culture The festival seeks high-quality video works that blend artistic inspiration wi
SERI Lugano Launches International Scientific Outreach Initiative on Light-Based Neuroscience and Pineal Gland Research18.5.2026 15:38:00 CEST | Press release
Researchers and clinicians from Switzerland expand interdisciplinary communication efforts integrating neuroscience, photobiomodulation, infrasound, and nutraceutical research As scientific interest in light-based stimulation, neuroendocrine regulation, and integrative medicine continues to grow internationally, the Switzerland Eye Research Institute (SERI Lugano) has launched a new international scientific outreach initiative focused on public engagement and interdisciplinary research communication in neuroscience and cellular modulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515840289/en/ Ophthalmologist Roberto Pinelli explains, in an engaging personal narrative style, his unique methods for using a combination of light, sound, and nutraceuticals to non-invasively activate the pineal gland to promote cellular rejuvenation, decrease aging, and improve overall well-being. Supported by case studies and peer-revi
TwentyTwo Real Estate to Acquire Terhills Resort in Belgium from LRM18.5.2026 15:00:00 CEST | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces it has agreed to acquire Terhills Resort in Belgium from LRM. The transaction is expected to close on 29 May 2026. Operated by Center Parcs, the premium holiday park spans 63 hectares and comprises 250 waterfront cottages alongside central leisure facilities, set within a unique natural environment at the gateway to Hoge Kempen National Park. Center Parcs will remain the operator of the resort for at least the next 10 years, ensuring continuity for guests and supporting the long-term positioning of the resort as a leading leisure destination in Limburg, one of Flanders’ most distinctive tourism regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513424487/en/ Opened in 2021, Terhills Resort forms part of the broader long-term transformation of the surrounding area into a leading nature, tourism and leisure destination.
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden18.5.2026 14:30:00 CEST | Press release
The state-of-the-art facility enhances support for complex modalities across all phases of drug developmentKey facts Thermo Fisher opensnew bioanalytical and biomarker laboratory in Gothenburg, Sweden Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions Supports pharmaceutical and biotechnology customers across all phases of drug development Helps customers globally accelerate innovation and bring new therapies to patients faster Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker servi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom